13.79
0.29 (2.15%)
| Previous Close | 13.50 |
| Open | 13.45 |
| Volume | 667,342 |
| Avg. Volume (3M) | 1,090,770 |
| Market Cap | 1,075,805,312 |
| Price / Sales | 5.90 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Phathom Pharmaceuticals, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 0.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.30 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalys Pacific, Llc | 30 Sep 2025 | 1,167,114 |
| 52 Weeks Range | ||
| Median | 16.00 (16.03%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 09 Dec 2025 | 16.00 (16.03%) | Hold | 14.21 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BASTA STEVEN L | 12.82 | 12.82 | 6,085 | 78,010 |
| COOK ANNE MARIE | 12.82 | 12.82 | 1,926 | 24,691 |
| Aggregate Net Quantity | 8,011 | |||
| Aggregate Net Value ($) | 102,701 | |||
| Aggregate Avg. Buy ($) | 12.82 | |||
| Aggregate Avg. Sell ($) | 12.82 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BASTA STEVEN L | Officer | 10 Feb 2026 | Acquired (+) | 12,362 | 12.82 | 158,481 |
| BASTA STEVEN L | Officer | 10 Feb 2026 | Disposed (-) | 6,277 | 12.82 | 80,471 |
| COOK ANNE MARIE | Officer | 10 Feb 2026 | Acquired (+) | 3,461 | 12.82 | 44,370 |
| COOK ANNE MARIE | Officer | 10 Feb 2026 | Disposed (-) | 1,535 | 12.82 | 19,679 |
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 |
| 07 Jan 2026 | Announcement | Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants |
| 07 Jan 2026 | Announcement | Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |
| 07 Jan 2026 | Announcement | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |